期刊文献+

Hepatocellular carcinoma in patients with chronic kidney disease

Hepatocellular carcinoma in patients with chronic kidney disease
下载PDF
导出
摘要 AIM: To investigate outcomes of hepatocellular carcinomas (HCCs) in patients with chronic kidney disease (CKD). METHODS: Four hundred and forty patients referred between 2000 and 2002 for management of HCCs were categorized according to their CKD stage, i.e. , estimated glomerular filtration rate (eGFR) > 90 (stage 1), 60-90 (stage 2), 30-60 (stage 3), 15-30 (stage 4), and < 15 (stage 5) mL/min per 1.73 m 2 , respectively. Demographic, clinical and laboratory data were collected and mortality rates and cause of mortality were analyzed. The mortality data were examined with Kaplan-meier method and the significance was tested using a log-rank test. An initial univariate Cox regression analysis was performed to compare the frequency of possible risk factors associated with mortality. To control for possible confounding factors, a multivariate Cox regression analysis (stepwise backward approach) was performed to analyze those factors that were significant in univariate models (P < 0.05) and met the assumptions of a proportional hazard model. RESULTS: Most HCC patients with CKD were elderly, with mean age of diagnosis of 60.6 ± 11.9 years, and mostly male (74.8%). Hepatitis B, C and B and C coinfection virus were positive in 61.6%, 45.7% and 14.1% of the patients, respectively. It was found that patients with stages 4 and 5 CKD were not only older (P = 0.001), but also had higher hepatitis C virus carrier rate (P = 0.001), lower serum albumin level (P = 0.001), lower platelet count (P = 0.037), longer prothrombin time (P = 0.001) as well as higher proportions of advanced cirrhosis (P = 0.002) and HCCs (P = 0.001) than patients with stages 1 and 2 CKD. At the end of analysis, 162 (36.9%) patients had died. Kaplan-Meier analysis revealed that patients with stages 4 and 5 CKD suffered lower cumulative survival than stages 1 and 2 CKD (log-rank test, χ 2 = 11.764, P = 0.003). In a multivariate Cox-regression model, it was confirmed that CKD stage [odds ratio (OR) = 1.988, 95%CI: 1.012-3.906, P = 0.046)], liver cirrhosis stage (OR = 3.571, 95%CI: 1.590-8.000,P = 0.002) and serum albumin level (OR = 0.657, 95%CI: 0.491-0.878, P = 0.005) were significant predictors for mortality in this population. CONCLUSION: HCC patients with stages 4 and 5 CKD had inferior survival than stages 1 and 2 CKD. This warrants further studies. AIM: To investigate outcomes of hepatocellular carcinomas (HCCs) in patients with chronic kidney disease (CKD). METHODS: Four hundred and forty patients referred between 2000 and 2002 for management of HCCs were categorized according to their CKD stage, i.e., estimated glomerular filtration rate (eGFR) > 90 (stage 1), 60-90 (stage 2), 30-60 (stage 3), 15-30 (stage 4), and < 15 (stage 5) mL/min per 1.73 m2, respectively. Demographic, clinical and laboratory data were collected and mortality rates and cause of mortality were analyzed. The mortality data were examined with Kaplan-meier method and the significance was tested using a log-rank test. An initial univariate Cox regression analysis was performed to compare the frequency of possible risk factors associated with mortality. To control for possible confounding factors, a multivariate Cox regression analysis (stepwise backward approach) was performed to analyze those factors that were significant in univariate models (P < 0.05) and met the assumptions of a proportional hazard model. RESULTS: Most HCC patients with CKD were elderly, with mean age of diagnosis of 60.6 ± 11.9 years, and mostly male (74.8%). Hepatitis B, C and B and C co-infection virus were positive in 61.6%, 45.7% and 14.1% of the patients, respectively. It was found that patients with stages 4 and 5 CKD were not only older (P = 0.001), but also had higher hepatitis C virus carrier rate (P = 0.001), lower serum albumin level (P = 0.001), lower platelet count (P = 0.037), longer prothrombin time (P = 0.001) as well as higher proportions of advanced cirrhosis (P = 0.002) and HCCs (P = 0.001) than patients with stages 1 and 2 CKD. At the end of analysis, 162 (36.9%) patients had died. Kaplan-Meier analysis revealed that patients with stages 4 and 5 CKD suffered lower cumulative survival than stages 1 and 2 CKD (log-rank test, χ2 = 11.764, P = 0.003). In a multivariate Cox-regression model, it was confirmed that CKD stage [odds ratio (OR) = 1.988, 95%CI: 1.012-3.906, P = 0.046)], liver cirrhosis stage (OR = 3.571, 95%CI: 1.590-8.000, P = 0.002) and serum albumin level (OR = 0.657, 95%CI: 0.491-0.878, P = 0.005) were significant predictors for mortality in this population. CONCLUSION: HCC patients with stages 4 and 5 CKD had inferior survival than stages 1 and 2 CKD. This warrants further studies.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第16期2466-2472,共7页 世界胃肠病学杂志(英文版)
关键词 HEPATOCELLULAR carcinoma HEPATITIS B VIRUS HEPATITIS C VIRUS Chronic kidney DISEASE END-STAGE RENAL DISEASE Hepatocellular carcinoma Hepatitis B virus Hepatitis C virus Chronic kidney disease End-stage renal disease
  • 相关文献

参考文献15

  • 1Shih-Ho Wang,Li-Mien Chen,Jane-Dar Lee.Increased extrinsic apoptotic pathway activity in patients with hepatocellular carcinoma following transarterial embolization[J].World Journal of Gastroenterology,2011,17(42):4675-4681. 被引量:1
  • 2Ignazio Grattagliano,Enzo Ubaldi,Leonilde Bonfrate,Piero Portincasa.Management of liver cirrhosis between primary care and specialists[J].World Journal of Gastroenterology,2011,17(18):2273-2282. 被引量:5
  • 3Chun-Nan Yeh,Wei-Chen Lee,Miin-Fu Chen.Hepatic resection for hepatocellular carcinoma in end-stage renal disease patients: Two decades of experience at Chang Gung Memorial Hospital[J].World Journal of Gastroenterology,2005,11(14):2067-2071. 被引量:3
  • 4Takashi Orii,Tetsuro Takayama,Izumi Haga,Tatsuya Fukumori,Noritoshi Amada.Efficacy of a liver resection for hepatocellular carcinoma in patients with chronic renal failure[J].Surgery Today.2008(4)
  • 5Tokihiko Sawada M.D., Ph.D.,Funji Kita M.D., Ph.D.,Kyu Rokkaku M.D., Ph.D.,Masato Kato M.D.,Mitsugi Shimoda M.D., Ph.D.,Keiichi Kubota M.D., Ph.D.Hepatectomy in patients with nonuremic minimal renal failure[J].Journal of Gastrointestinal Surgery.2006(5)
  • 6Yen T H,Lin J L,Lin-Tan D T,et al.Association between bodymass and mortality in maintenance hemodialysis patients[].TherApher Dial.2010
  • 7Johnson DW,Dent H,Yao Q,et al.Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries:analysis of registry data[].Nephrology Dialysis Transplantation.2009
  • 8Stewart J H,Buccianti G,Agodoa L,et al.Cancers of the kid-ney and urinary tract in patients on dialysis for end-stage renal disease:analysis of data fromthe United States,Europe,and Australia and New Zealand[].Journal of the American Society of Nephrology.2003
  • 9Zevin,D,Turani,H,Cohen,A,Levi,J.Androgen-associated hepatoma in a hemodialysis patient[].Nephron.1981
  • 10Naugler WE,Sakurai T,Kim S,Maeda S,Kim K,Elsharkawy AM,Karin M.Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production[].Science.2007

二级参考文献50

  • 1范建高,蔡晓波.成人肝硬化腹水的诊断与治疗[J].肝脏,2004,9(3):193-195. 被引量:120
  • 2D.Festi,S.Capodicasa,L.Sandri,L.Colaiocco-Ferrante,T.Staniscia,E.Vitacolonna,A.Vestito,R.Simoni,G.Mazzella,P.Portincasa,E.Roda,A.Colecchia.Measurement of hepatic functional mass by means of ^(13)C-methacetin and ^(13)C-phenylalanine breath tests in chronic liver disease: Comparison with Child-Pugh score and serum bile acid levels[J].World Journal of Gastroenterology,2005,11(1):142-148. 被引量:35
  • 3McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 2006; 136:125-135.
  • 4Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, Shinkai N, Hirashima N, Hasegawa I, Ohno T, Ueda R, Mizokami M. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol 2007; 42:298-305.
  • 5Kim KR, Moon HE, Kim KW. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) 2002; 80:703-714.
  • 6Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma ceils through the induction of hexokinase II expression. J Hepatol 2005; 42:358-364.
  • 7Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
  • 8Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 2008; 8:1623-1641.
  • 9Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49:523-529.
  • 10Kobayashi N, Ishii M, Ueno Y, Kisara N, Chida N, Iwasaki T, Toyota T. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 1999; 19:25-31.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部